JGC
BLU

J. Goldman & Co’s BELLUS Health Inc. BLU Stock Holding History

J. Goldman & Co’s Portfolio BLU Stock Details BLU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-36,500
Closed -$294K – 491
2021
Q4 		$294K Buy
+36,500
New +$242K 0.02% 303

Other funds holding BLU

CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
VAM
Vazirani Asset Management New York $43.4M AUM 84.05% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
GLAM
Gardner Lewis Asset Management Chadds Ford, Pennsylvania $462M AUM 65.29% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Amundi
Amundi Paris, France $367B AUM 31.23% 1-Year Est. Return
SAM
Shell Asset Management The Hague, Netherlands $996M AUM 26.19% 1-Year Est. Return
Canada Life
Canada Life Winnipeg, Manitoba, Canada $55.8B AUM 26.04% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
LC
Lindbrook Capital Calabasas, California $1.08B AUM 10.14% 1-Year Est. Return

J. Goldman & Co's BLU Position: Q2 2023 in Review

J. Goldman & Co sold out of BELLUS Health Inc. (BLU) in Q2 2023, closing a stake of 54,000 shares — an estimated $389K sold.

J. Goldman & Co first reported a position in BLU in Q4 2021 and held it in 6 quarters. The position peaked at $1.61M in Q4 2021. 11 funds tracked by Wall St. Rank hold BLU as of Q2 2023.

  • J. Goldman & Co reported no remaining BELLUS Health Inc. position as of Q2 2023 after selling out during the quarter.
  • J. Goldman & Co sold 54,000 BELLUS Health Inc. shares in Q2 2023, an estimated $389K.
  • J. Goldman & Co first reported a position in BELLUS Health Inc. in Q4 2021 and held it in 6 quarters.
  • J. Goldman & Co's BELLUS Health Inc. position peaked at $1.61M in Q4 2021.
  • 11 funds tracked by Wall St. Rank held BELLUS Health Inc. as of Q2 2023.

Based on J. Goldman & Co's 13F filing for Q2 2023, filed 14 Aug 2023.